All Press Releases
XEN-D0501 can progress to clinical trials up to 3-month duration after being found safe in 13-week preclinical oral safety studies
Malmö, March 29, 2023 Download the press release as PDF here PILA PHARMA AB (publ) (FN STO: PILA) today publishes that 13-week preclinical oral safety studies with the development candidate XEN-D0501 have completed without adverse signals. Previously, it has been communicated that the “rodent” part had completed without adverse signals and that the “non-rodent” also completed the in-life phase without…
PILA PHARMA publishes year-end report (1 January – 31 December 2022)
Malmö, 28 February 2023 Download the press release as PDF here PILA PHARMA AB (publ) (FN STO: PILA) today publishes the Company´s year-end report for the period January – December 2022. The report can be found on the Company´s website:https://pilapharma.com/investors/finansiell-information/ SUMMARY OF YEAR-END REPORT Fourth quarter (1 October - 31 December 2022) Revenue was 413 kSEK (719) Operating loss (EBIT) was -1…
PILA PHARMA publicerar bokslutskommuniké (1 januari-31 december 2022)
Malmö, 28 februari 2023 Läs pressmeddelandet som PDF här PILA PHARMA AB (publ) (FN STO: PILA) publicerar i dag bolagets bokslutskommuniké för perioden januari – december 2022 som finns att ta del av på bolagets hemsida: https://pilapharma.com/investors/finansiell-information/ SAMMANFATTNING AV BOKSLUTSKOMMUNIKÉ Fjärde kvartalet (1 oktober - 31 december 2022) Rörelsens intäkter uppgick till 413 kSEK (719) Rörelseresultatet (EBIT) uppgick till -1 951…